Trial Profile
Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2014
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Sep 2014 New trial record